Antiphospholipid antibodies — We are not quite there yetURBANUS, Rolf T; DE GROOT, Philip G.Blood reviews. 2011, Vol 25, Num 2, pp 97-106, issn 0268-960X, 10 p.Article

The significance of autoantibodies against β₂-glycoprotein IDE GROOT, Philip G; URBANUS, Rolf T.Blood. 2012, Vol 120, Num 2, pp 266-274, issn 0006-4971, 9 p.Article

The role of von Willebrand factor in platelet functionDE GROOT, Philip G.Seminars in thrombosis and hemostasis. 2002, Vol 28, Num 2, pp 133-138, issn 0094-6176Article

Haemostatic abnormalities in patients with liver diseaseLISMAN, Ton; LEEBEEK, Frank W. G; DE GROOT, Philip G et al.Journal of hepatology. 2002, Vol 37, Num 2, pp 280-287, issn 0168-8278Article

A nanobody-based method for tracking factor XII activation in plasma : Kallikreins: Pathobiology and association to diseaseDE MAAT, Steven; VAN DOOREMALEN, Sanne; DE GROOT, Philip G et al.Thrombosis and haemostasis. 2013, Vol 110, Num 3, pp 458-468, issn 0340-6245, 11 p.Article

Evolutionary conservation of the lipopolysaccharide binding site of β₂-glycoprotein IAGAR, Cetin; DE GROOT, Philip G; MARQUART, J. Arnoud et al.Thrombosis and haemostasis. 2011, Vol 106, Num 6, pp 1069-1075, issn 0340-6245, 7 p.Article

The interaction of recombinant factor VIIa with platelet glycoprotein IbLISMAN, Ton; DE GROOT, Philip G.Thrombosis research. 2010, Vol 125, issn 0049-3848, S13-S15, SUP1Article

Current insight into diagnostics and pathophysiology of the antiphospolipid syndromeURBANUS, Rolf T; DERKSEN, Ronald H. M. W; DE GROOT, Philip G et al.Blood reviews. 2008, Vol 22, Num 2, pp 93-105, issn 0268-960X, 13 p.Article

The Future of Antiphospholipid Antibody TestingDE GROOT, Philip G; URBANUS, Rolf T.Seminars in thrombosis and hemostasis. 2012, Vol 38, Num 4, pp 412-419, issn 0094-6176, 8 p.Article

Tissue Factor-Independent Effects of Recombinant Factor VIIa on HemostasisWEETERINGS, Cees; LISMAN, Ton; DE GROOT, Philip G et al.Seminars in hematology. 2008, Vol 45, Num 2, issn 0037-1963, S12-S15, SUP1Conference Paper

Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factorLISMAN, Ton; ADELMEIJER, Jelle; NIEUWENHUIS, H. Karel et al.Blood coagulation & fibrinolysis. 2003, Vol 14, Num 6, pp 557-562, issn 0957-5235, 6 p.Article

Up-regulation of platelet activation in hemophilia AVAN BLADEL, Esther R; ROEST, Mark; DE GROOT, Philip G et al.Haematologica (Roma). 2011, Vol 96, Num 6, pp 888-895, issn 0390-6078, 8 p.Article

Tests for lupus anticoagulant revisitedDERKSEN, Ronald H. W. M; DE GROOT, Philip G.Thrombosis research. 2004, Vol 114, Num 5-6, pp 521-526, issn 0049-3848, 6 p.Conference Paper

Regulation of von Willebrand factor-platelet interactionsLENTING, Peter J; PEGON, Julie N; GROOT, Evelyn et al.Thrombosis and haemostasis. 2010, Vol 104, Num 3, pp 449-455, issn 0340-6245, 7 p.Conference Paper

Reduced plasma fibrinolytic potential is a risk factor for venous thrombosisLISMAN, Ton; DE GROOT, Philip G; MEIJERS, Joost C. M et al.Blood. 2005, Vol 105, Num 3, pp 1102-1105, issn 0006-4971, 4 p.Article

Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor-independent fibrin generationLISMAN, Ton; ADELMEIJER, Jelle; HEIJNEN, Harry F. G et al.Blood. 2004, Vol 103, Num 5, pp 1720-1727, issn 0006-4971, 8 p.Article

The glycoprotein Ib-DC-V complex contributes to tissue factor-independent thrombin generation by recombinant factor Vila on the activated platelet surface. CommentatyHOFFMAN, Maureane; WEETERINGS, Cees; DE GROOT, Philip G et al.Blood. 2008, Vol 112, Num 8, issn 0006-4971, 3002-3003, 3227-3233 [9 p.]Article

The presence of active von Willebrand factor under various pathological conditionsGROOT, Evelyn; DE GROOT, Philip G; FIJNHEER, Rob et al.Current opinion in hematology. 2007, Vol 14, Num 3, pp 284-289, issn 1065-6251, 6 p.Article

Glycoprotein Ibα-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flowWEETERINGS, Cees; ADELMEIJER, Jelle; MYLES, Timothy et al.Arteriosclerosis, thrombosis, and vascular biology. 2006, Vol 26, Num 3, pp 670-675, issn 1079-5642, 6 p.Article

Recombinant factor VIIa enhances deposition of platelets with congenital or acquired α_IIbβ₃ deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generationLISMAN, Ton; MOSCHATSIS, Sultana; ADELMEIJER, Jelle et al.Blood. 2003, Vol 101, Num 5, pp 1864-1870, issn 0006-4971, 7 p.Article

Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and BVALLS SERON, Mercedes; PLUG, Tom; ARNOUD MARQUART, J et al.Thrombosis and haemostasis. 2011, Vol 106, Num 4, pp 609-616, issn 0340-6245, 8 p.Article

β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndromeAGAR, Cetin; VAN OS, Gwendolyn M. A; MÖRGELIN, Matthias et al.Blood. 2010, Vol 116, Num 8, pp 1336-1343, issn 0006-4971, 8 p.Article

Novel molecular defect in the platelet ADP receptor P2Y₁₂of a patient with haemorrhagic diathesisREMIJN, Jasper A; IJSSELDIJK, Martin J. W; STRUNK, Annuska L. M et al.Clinical chemistry and laboratory medicine. 2007, Vol 45, Num 2, pp 187-189, issn 1434-6621, 3 p.Article

Elevated levels of D-dimer and fragment 1+2 upon central venous catheter insertion and factor V leiden predict subclavian vein thrombosisJANSEN, Flip H; VAN DER STRAATEN, Hanneke M; ROEST, Mark et al.Haematologica (Roma). 2005, Vol 90, Num 4, pp 499-504, issn 0390-6078, 6 p.Article

β₂-Glycoprotein I, the playmaker of the antiphospholipid syndromeBAS DE LAAT, H; DERKSEN, Ronald H. W. M; DE GROOT, Philip G et al.Clinical immunology (Orlando, Fla. Print). 2004, Vol 112, Num 2, pp 161-168, issn 1521-6616, 8 p.Article